Testing effectiveness (Phase 2)Study completedNCT00299741What this trial is testingStudy of SU11248 in Men With Advanced Prostate CancerWho this might be right forProstate Cancer Massachusetts General Hospital 36
Early research (Phase 1)Ended earlyNCT00493766What this trial is testingSafety of LBH589 Alone and in Combination With IV Docetaxel and PrednisoneWho this might be right forHormone Refractory Prostate Cancer Novartis Pharmaceuticals 16
Early research (Phase 1)Study completedNCT00891345What this trial is testingSafety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer TherapyWho this might be right forHormone-refractory Prostate Cancer CytoVac A/S 13
Testing effectiveness (Phase 2)Ended earlyNCT05551117What this trial is testingVobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsWho this might be right forCastration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more MacroGenics 192
Testing effectiveness (Phase 2)Study completedNCT02097303What this trial is testingOpen Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone MetastasisWho this might be right forProstate Cancer Carolina Research Professionals, LLC 36
Not applicableEnded earlyNCT00358098What this trial is testingStudy to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer AHS Cancer Control Alberta 51
Early research (Phase 1)Study completedNCT00314782What this trial is testingPhase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPCWho this might be right forProstate Cancer AstraZeneca 44
Large-scale testing (Phase 3)Active Not RecruitingNCT06551324What this trial is testingLearn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Who this might be right forMetastatic Castrate Resistant Prostate Cancer (mCRPC) Pfizer 600
Testing effectiveness (Phase 2)Study completedNCT00104650What this trial is testingStudy of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesWho this might be right forBone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Amgen 111
Large-scale testing (Phase 3)Study completedNCT00321620What this trial is testingStudy of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate CancerWho this might be right forBone Metastases Amgen 1,904
Testing effectiveness (Phase 2)Ended earlyNCT00048659What this trial is testingYM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone TherapyWho this might be right forHormone-Refractory Prostate CancerProstatic Neoplasms Astellas Pharma Inc
Testing effectiveness (Phase 2)Ended earlyNCT00527124What this trial is testingDocetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyWho this might be right forAdenocarcinoma of the ProstateStage IV Prostate Cancer National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Study completedNCT00258388What this trial is testingDocetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyWho this might be right forProstate Cancer NCIC Clinical Trials Group 82
Early research (Phase 1)Study completedNCT00005048What this trial is testingEstramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyWho this might be right forProstate Cancer NYU Langone Health
Testing effectiveness (Phase 2)Ended earlyNCT01828476What this trial is testingNavitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate CancerWho this might be right forProstate Cancer Rutgers, The State University of New Jersey 13
Testing effectiveness (Phase 2)UnknownNCT00003717What this trial is testingPaclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate CancerWho this might be right forProstate Cancer St. Barnabas Medical Center 17
Testing effectiveness (Phase 2)Study completedNCT00554918What this trial is testingDocetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone TherapyWho this might be right forMetastatic CancerProstate Cancer University Hospital Birmingham 300
Testing effectiveness (Phase 2)UnknownNCT00550810What this trial is testingSutent Maintenance After Response to TaxotereWho this might be right forProstate CancerHormone Refractory Alberta Health services 30
Testing effectiveness (Phase 2)Study completedNCT00005820What this trial is testingNitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone TherapyWho this might be right forProstate Cancer Alliance for Clinical Trials in Oncology 35
Early research (Phase 1)Study completedNCT00510718What this trial is testingMDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate CancerWho this might be right forProstate CancerHormone Refractory Prostate Cancer Pfizer 140